Natco Pharma is among the top stocks in terms of its durability score, but is seeing increasingly expensive valuation since sharp gains over the past one year. The company was among the top share price gainers today after news that it raised Rs. 915 crore via QIP. The company's committee of directors decided to allocate 1 crore shares at issue price of Rs 915 apiece.

Natco has plans overall to raise Rs. 1,500 crore via equity, in order to invest into the complex generics space in the US over the long-term. The company's gTamiflu offering tends to have strong sales in the flu season in the US between November to March, and therefore analysts expect it to boost the sales for that quarter.